Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Inclusion Criteria:

- Written informed consent/assent

- General good health

- Diagnosis of asthma as defined by the National Institutes of Health (NIH)

- A best FEV1 of 40%-85% of the predicted normal value during the screening visit (SV)

- Subjects need to demonstrate a ≥ 15% reversibility of FEV1 within 30 minutes
following 4 inhalations of albuterol inhalation aerosol (if required, spacers are
permitted for reversibility testing) at the SV.

- Other inclusion criteria apply

Exclusion Criteria:

- History of life-threatening asthma that is defined for this protocol as an asthma
episode that required intubation.

- Culture-documented or suspected bacterial or viral infection of the upper or lower
respiratory tract, sinus, or middle ear that is not resolved within 2 weeks prior to
the SV.

- Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A
subject must not have had any hospitalization for asthma within 6 months prior to the
SV.

- Taking long-acting β-agonists within 2 weeks of the SV

- Other exclusion criteria apply.